Compare · KURA vs LLY
KURA vs LLY
Side-by-side comparison of Kura Oncology Inc. (KURA) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KURA and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 960.6x KURA ($1.21B).
- LLY has been more active in the news (16 items in the past 4 weeks vs 10 for KURA).
- LLY has more recent analyst coverage (25 ratings vs 18 for KURA).
- Company
- Kura Oncology Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $1.21B
- $1.16T
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 16
- Recent ratings
- 18
- 25
Kura Oncology Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest KURA
- Chief Commercial Officer Powl Brian T. sold $51,663 worth of shares (4,345 units at $11.89) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 169,269 units (SEC Form 4)
- President and CEO Wilson Troy Edward bought $1,239,000 worth of shares (100,000 units at $12.39) (SEC Form 4)
- Chief Legal Officer Bair Teresa Brophy sold $397,681 worth of shares (31,487 units at $12.63) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 195,444 units (SEC Form 4)
- President and CEO Wilson Troy Edward bought $1,112,000 worth of shares (100,000 units at $11.12) (SEC Form 4)
- SEC Form 10-Q filed by Kura Oncology Inc.
- Kura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kura Oncology Reports Second Quarter 2026 Financial Results
- Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Kura Oncology to Report Second Quarter Financial Results
Latest LLY
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
- SVP, Finance, & CAO Zakrowski Donald A sold $2,370,020 worth of shares (2,000 units at $1,185.01) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 1,526 units (SEC Form 4)